New pill shows promise for advanced breast cancer – Real-World trial underway

NCT ID NCT05578053

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new oral drug called dalpiciclib in 420 people with hormone receptor-positive advanced breast cancer. Researchers are watching how well it works and what side effects occur in everyday medical practice, not a strict lab setting. The goal is to see if it can help control the disease longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalpiciclib (a CDK4/6 inhibitor pill)
What this could lead to: If successful, this could show that dalpiciclib is a safe and effective option for controlling advanced HR+ breast cancer in everyday clinical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and may not lead to a new standard of care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The Fourth hospital of Hebei University
RECRUITING

Shijiazhuang, Hebei, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.